Want to see AU:RHY full AI Analyst Report?

Rhythm Biosciences Ltd. (RHY) Price & Analysis

13 Followers

RHY Stock Chart & Stats

AU$0.09

-AU$0.01(-11.11%)

At close: Jul 27 4:00 PM EDT

AU$0.09

-AU$0.01(-11.11%)

Day’s Range― - ―

52-Week RangeAU$0.06 - AU$0.28

Previous CloseN/A

Volume360.17K

Average Volume (3M)462.98K

Market Cap

AU$28.40M

Enterprise ValueAU$37.54M

Total Cash (Recent Filing)AU$1.73M

Total Debt (Recent Filing)AU$262.44K

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding364,059,840

10 Day Avg. Volume510,821

30 Day Avg. Volume462,976

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)22.03

Price to Sales (P/S)4.56

P/FCF Ratio-4.94

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Focused IVD Product StrategyA focused business model targeting a single diagnostic indication (colorectal cancer screening) concentrates R&D and commercialization resources. That specialization can accelerate clinical validation, regulatory clarity, and go-to-market execution, improving chances to establish a durable niche and scale unit economics when adoption rises.

High Gross Margin ProfileA high gross margin indicates attractive product-level economics that can absorb R&D and commercialization fixed costs as volumes grow. Sustained high gross margins provide long-term operating leverage, enabling profitability once revenue scale improves and helping the company fund reinvestment or reduce reliance on external capital.

Improving Free Cash Flow TrendAn improving free cash flow trend signals progress toward converting accounting losses into cash-generative operations. If continued, this reduces financing needs, improves financial flexibility for commercial rollouts, and strengthens the balance sheet over months, supporting sustained investment in product development and market expansion.

Bears Say

Sharp Revenue DeclineA recent 42.87% revenue decline combined with persistent negative margins indicates weak commercial traction and volatile demand. Over the medium term this undermines scale economics, prolongs the path to breakeven, and forces higher relative spending on sales and R&D to rebuild growth, pressuring cash and returns.

Elevated LeverageA debt-to-equity ratio of 1.68 denotes meaningful leverage for a development-stage diagnostics company. High debt increases fixed interest costs, reduces flexibility to invest in regulatory approvals or commercialization, and raises refinancing risk. This structural burden can force constrained growth or dilutive recapitalizations.

Negative Operating Cash FlowSustained negative operating cash flow signals ongoing cash burn from core operations, meaning the company likely needs external funding to sustain development and commercialization. That dependence raises execution risk, may dilute shareholders, and limits the firm's ability to make durable investments in market expansion or manufacturing scale.

Rhythm Biosciences Ltd. News

Rhythm Biosciences Builds Momentum in ColoSTAT Rollout and Global Partnerships

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences reported solid progress in...

3d ago

RHY

Rhythm Biosciences Targets GPs With ColoSTAT Campaign After Market Research

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an announcement. Rhythm Biosciences has completed in-field market research with...

1M ago

RHY

Rhythm Biosciences Frames ASX Position While Emphasising Limits of Investor Presentation

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has released an investor...

2M ago

RHY

Rhythm Biosciences expands ColoSTAT access program as clinician uptake grows

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an update. Rhythm Biosciences has expanded its ColoSTAT Clinical Access...

2M ago

RHY

Rhythm Biosciences’ ColoSTAT Test Gains Early Clinical Traction in Underserved CRC Patients

An announcement from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences reported early clinical adoption...

3M ago

RHY

Rhythm Biosciences Schedules Investor Webinar to Update on Cancer Diagnostics Progress

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences will host an investor webinar on...

3M ago

RHY

Rhythm Biosciences Cuts Underwritten Options Proceeds After Administrative Error

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences has revised the final proceeds from...

3M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for New Options

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an update. Rhythm Biosciences has applied to the ASX for...

4M ago

RHY

Rhythm Biosciences Issues New Shares and Confirms Regulatory Compliance

An update from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences has issued 18,834,007 ordinary...

4M ago

RHY

Rhythm Biosciences Seeks ASX Quotation for 18.8 Million New Shares

The latest update is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has applied to the...

4M ago

RHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.06 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$28.40M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

Rhythm Biosciences Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 26 days.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Feb 18, 2026. The company reported -AU$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.007.

Is Rhythm Biosciences Ltd. overvalued?

According to Wall Street analysts Rhythm Biosciences Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.381%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-47.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rhythm Biosciences Ltd.

Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.